Andrew
Senior Member
- Messages
- 2,523
- Location
- Los Angeles, USA
What is the consequence of a research center patenting an illness treatment? Do other treatment centers have to pay them a royalty every time they treat someone the same way.
Welcome to Phoenix Rising!
Created in 2008, Phoenix Rising is the largest and oldest forum dedicated to furthering the understanding of, and finding treatments for, complex chronic illnesses such as chronic fatigue syndrome (ME/CFS), fibromyalgia, long COVID, postural orthostatic tachycardia syndrome (POTS), mast cell activation syndrome (MCAS), and allied diseases.
To become a member, simply click the Register button at the top right.
Rituximab was developed by IDEC Pharmaceuticals (formed in 1986 by Ivor Royston and Howard Birndorf) under the name IDEC-C2B8.[1]
Based on its safety and effectiveness in clinical trials,[2] rituximab was approved by the U.S. Food and Drug Administration in 1997 to treat B-cell non-Hodgkin lymphomas resistant to other chemotherapy regimens.[3] Rituximab, in combination with CHOP chemotherapy, is now a standard therapy in the initial treatment of diffuse large B-cell lymphoma and many other B-cell lymphomas.[citation needed] In 2010 it was approved by the European Commission for maintenance treatment after initial treatment of follicular lymphoma.[4]
Rituximab is currently co-marketed by Biogen Idec and Genentech in the U.S., by HoffmannLa Roche in Canada and the European Union, and by Chugai Pharmaceuticals and Zenyaku Kogyo in Japan.